Correlation of DDLS Grading to OCT, HRT, and HVF
The purpose of this study is to determine how well the DDLS (Disc Damage Likelihood Scale) (which is a method used by the eye doctor to evaluate how healthy the optic nerve is) measures up to the standard glaucoma tests: OCT (Optical Coherence Tomography), the HRT (Heidelberg Retinal Tomography) and the HVF (Humphrey Visual Field).
Description
The Disc Damage Likelihood Scale (DDLS) has been shown to be a reproducible method for clinicians to evaluate the optic nerve for glaucomatous damage and is highly correlated to diagnosis of glaucoma, severity of glaucoma as evidenced by visual field loss and Heidelberg Retina Tomography (HRT) evaluation. In comparison with the commonly used cup-disc ratio, the DDLS has less inter-observer variation and captures glaucomatous aspects of the optic nerve not assessed by the cup-disc ratio. The optic nerve imagers do not have the potential to completely replace the clinical examination of the optic nerve since they do not assess many critical features such as optic nerve pallor, hemorrhages, asymmetry of disc size, edema, etc. The DDLS presents the opportunity to provide a system to clinicians to increase the quality and objectivity of clinical optic nerve evaluation. The purpose of this study is to investigate the correlation of the DDLS grading to OCT, HRT and HVF testing of glaucomatous and normal optic nerves.
Status: Completed (N/A). Started on March 1st, 2007.
Enrollment: 101 subjects
Study Type: Observational
Study Design:
- Observational Model: Cohort
- Time Perspective: Prospective
Conditions:
Interventions:
Eligibility
Inclusion Criteria:
Vision 20/50 or better
Less than 3 diopters of astigmatism
3 diopters or less of myopia or hyperopia
Pattern Standard Deviation on HVF less than 2.5dB in normals
Pattern Standard Deviation on HVF greater than 2.5 db in glaucoma patients
Exclusion Criteria:
- Gender
Both
- Mininum Age
45 Years
- Maximum Age
85 Years
- Healthy Volunteers
Accepts Healthy Volunteers
Resources
Source: Wills Eye
Authority: United States: Institutional Review Board
Locations
-
Wills Eye Glaucoma Service
Philadelphia
Pennsylvania
19107
United States
Officials
Jonathan S Myers, MD (Principal Investigator, Wills Eye Glaucoma Service)
Sponsors
Wills Eye (Lead Sponsor)
Merck (Collaborator)
References
None.
Links
None.
- Date Verified
- November 1st, 2008
- First Received
- January 25th, 2010
- Last Changed
- January 25th, 2010
Information obtained from ClinicalTrials.gov on June 09, 2011. Link to the current ClinicalTrials.gov record.
All data in the Healia Clinical Trials Information Database and content displayed by the Healia Clinical Trials Search Engine are licensed from the National Institutes of Health (National Library of Medicine), which collects and maintains the data.
The Healia Clinical Trials Search Engine searches the data set at clinicaltrials.gov, providing up-to-date information about current clinical trials. In the Healia Clinical Trials Database you can find information on new experimental drugs, medical devices, and other types of treatments for all types of diseases. Each clinical trial description includes information about the phase of the trial (phase I, phase II, or phase III), the trial’s methods, such as whether it is a randomized, placebo controlled, double blind study, and the status of the trial including whether or not the trial is currently enrolling new participants.